Neuromuscular blockers and reversal
The neuromuscular junction as a drug target, how depolarising and non-depolarising blockade differ in mechanism, monitoring and reversal, the pharmacology of suxamethonium and the aminosteroid and benzylisoquinolinium agents, the conditions that alter the response, and the reversal agents and their mechanisms.
By the end of this page you should be able to
- Describe transmission at the neuromuscular junction and the receptor targeted by blocking drugs.
- Contrast depolarising and non-depolarising blockade in mechanism, clinical signs, monitoring pattern and reversibility.
- Describe the pharmacology of suxamethonium, including its adverse effects and the conditions that prolong it.
- Compare the aminosteroid and benzylisoquinolinium agents by clearance and adverse effect profile.
- Explain how disease, electrolytes, temperature and other drugs alter the response to these agents.
- Describe the mechanisms of anticholinesterase reversal and of sugammadex.
The junction
An action potential in the motor nerve opens voltage-gated calcium channels, and calcium entry triggers release of acetylcholine from vesicles. Acetylcholine crosses the cleft and binds the two alpha subunits of the nicotinic (N-M) receptor, a ligand-gated cation channel on the folded postsynaptic membrane. Sodium entry depolarises the end plate; when the end plate potential reaches threshold, a muscle action potential propagates and calcium is released from the sarcoplasmic reticulum. Transmission is terminated by acetylcholinesterase in the cleft, which hydrolyses acetylcholine within milliseconds.
Two features of the junction matter pharmacologically. First, there is a large safety margin: many more receptors exist than are needed, so a substantial proportion can be blocked before any clinical weakness appears, and conversely clinical recovery can occur while many receptors are still occupied. Second, presynaptic receptors support the mobilisation of further vesicles during repetitive stimulation, and blocking them is what produces fade on repeated stimuli.
Two kinds of block
- Depolarising block (suxamethonium): the drug is an agonist. It binds the receptor and, because it is not broken down in the cleft, holds the channel open. The end plate stays depolarised and the surrounding membrane cannot generate another action potential. Clinically there are fasciculations first, then paralysis. On monitoring there is no fade (all four twitches are equally reduced) and no post-tetanic potentiation, and an anticholinesterase prolongs rather than reverses the block. With prolonged or repeated exposure the character changes to a block with fade (phase II block).
- Non-depolarising block: the drug is a competitive antagonist. It occupies the receptor without opening it, so the end plate potential never reaches threshold. There is no fasciculation, monitoring shows fade and post-tetanic potentiation (the tetanus mobilises more acetylcholine, which competes with the drug), and the block is reversible by raising the acetylcholine concentration or by removing the drug.
- Monitoring: the train-of-four ratio compares the fourth twitch with the first. The pattern separates the two kinds of block and tracks recovery; the key clinical caveat is that a train-of-four that looks normal to the eye does not exclude residual paralysis, which is why quantitative monitoring is preferred and why reversal is given rather than assumed.
Suxamethonium
- Structure and kinetics: two acetylcholine molecules joined. It is hydrolysed by plasma (pseudo)cholinesterase, not by the enzyme in the cleft, and its very short duration reflects that rapid hydrolysis; it does not depend on renal or hepatic clearance. This gives it the fastest onset and the shortest offset of the group, which is why it has been the traditional agent for rapid sequence intubation.
- Prolonged block occurs with inherited pseudocholinesterase deficiency (duration varies with the genotype, from a modest extension to hours), and with reduced enzyme activity in liver disease, pregnancy, malnutrition, and with drugs such as organophosphates, some anticholinesterases and metoclopramide.
- Potassium release: depolarisation of every muscle cell releases potassium, with a small rise in healthy patients but a dangerous rise where extrajunctional nicotinic receptors have been upregulated: burns beyond about a day until healing is complete, denervation injury such as spinal cord or stroke after the first few days, prolonged immobility and critical illness myopathy, and chronic neuromuscular disease. In these patients the drug is avoided because the rise can cause arrest.
- Other adverse effects: myalgia (related to fasciculation), raised intragastric, intraocular and intracranial pressure, bradycardia and other arrhythmias especially with repeat exposure or in children (muscarinic stimulation), masseter spasm, prolonged block in myotonic disorders, and malignant hyperthermia, for which it is a trigger.
- Malignant hyperthermia is worth knowing as a mechanism: an inherited abnormality of the ryanodine receptor leads to uncontrolled calcium release from the sarcoplasmic reticulum, causing sustained contraction, a massive rise in metabolic rate, hypercapnia, hyperthermia, rigidity, rhabdomyolysis and acidosis. Dantrolene is the specific agent, acting by inhibiting that calcium release; it has no role in other causes of hyperthermia.
The non-depolarising agents
- Aminosteroids (rocuronium, vecuronium, pancuronium): rocuronium has a rapid onset that approaches suxamethonium when a larger quantity is used, and an intermediate duration; vecuronium is intermediate; pancuronium is long-acting and causes tachycardia through vagolytic and sympathomimetic effects. They are cleared hepatically and renally, so they accumulate in organ failure, and vecuronium has an active metabolite that accumulates in critical illness.
- Benzylisoquinoliniums (atracurium, cisatracurium, mivacurium): atracurium is remarkable for organ-independent elimination, by Hofmann degradation (spontaneous, temperature and pH dependent) and ester hydrolysis, which makes it attractive in renal and hepatic failure; it causes histamine release with flushing and hypotension, and its metabolite laudanosine is proconvulsant at high concentrations. Cisatracurium is the single isomer with far less histamine release.
- Choosing between them is a pharmacological argument rather than a preference: speed of onset for airway control, duration relative to the expected procedure, organ function, haemodynamic tolerance of histamine release, and whether rapid reversal must be available.
- The problem with long blockade in the emergency setting is that it conceals seizures and neurological deterioration and prevents assessment, so sedation must be given with it and the neurological examination planned around it.
Altered responses and reversal
- Potentiated (block deeper or longer): hypothermia, respiratory and metabolic acidosis, hypokalaemia, hypocalcaemia, hypermagnesaemia, aminoglycoside and some other antibiotics, volatile anaesthetics, local anaesthetics, lithium, and myasthenia gravis (fewer functional receptors, so markedly sensitive to non-depolarising agents and relatively resistant to suxamethonium).
- Resistant (block less effective): upregulation of receptors in burns, denervation and prolonged immobility (which also makes these patients sensitive to depolarising agents and at risk of hyperkalaemia), chronic anticonvulsant use, and Lambert-Eaton syndrome, where presynaptic calcium channel antibodies make patients sensitive to both classes.
- Anticholinesterase reversal (neostigmine): inhibits acetylcholinesterase, so acetylcholine accumulates in the cleft and outcompetes the antagonist. Two consequences follow from the mechanism. It cannot reverse a deep block, because there is a ceiling to how much acetylcholine can accumulate, and it floods muscarinic receptors elsewhere, causing bradycardia, bronchospasm, salivation, increased gut activity and miosis, so an antimuscarinic (atropine or glycopyrrolate) is given with it.
- Sugammadex works by a completely different principle: a modified gamma-cyclodextrin that encapsulates the aminosteroid molecule in plasma, forming an inactive complex and creating a concentration gradient that draws drug away from the junction. It therefore reverses even a deep block within minutes, has no muscarinic effects, and works only for the aminosteroids; the complex is renally excreted. It does not reverse the benzylisoquinoliniums or suxamethonium.
- Residual paralysis matters clinically: it impairs airway protection, swallowing and the ventilatory response to hypoxia, so extubation is based on objective recovery, not on the patient moving. For quantities and specific regimens, consult the Australian Medicines Handbook or local protocols.
Making the answer flow
- Describe the junction first, then explain each block as agonist or antagonist; the monitoring pattern and reversibility then follow without memorising.
- For suxamethonium, group the adverse effects by mechanism: depolarisation (potassium, myalgia, pressures), muscarinic (bradycardia), and metabolic (malignant hyperthermia, cholinesterase deficiency).
- Explain receptor upregulation once, then use it to answer burns, denervation and critical illness questions.
- Contrast the two reversal mechanisms: competition versus encapsulation.
Where marks are lost
- Saying an anticholinesterase reverses suxamethonium.
- Claiming fade occurs with a pure depolarising block.
- Giving suxamethonium a few days after a spinal cord injury or a major burn.
- Forgetting that sugammadex has no effect on atracurium or cisatracurium.
- Treating a clinically normal train-of-four as proof of full recovery.
Where this meets the emergency department
- Avoid suxamethonium a few days or more after a burn, spinal cord injury or prolonged immobility: upregulated receptors release enough potassium to cause arrest.
- Paralysis hides seizures and neurological deterioration, so always pair it with sedation and plan when you will next be able to examine the patient.
Viva questions
Answer each one aloud, as you would to an examiner, before you open the model points.
- 1.
Describe transmission at the neuromuscular junction.
Show answer
- Nerve action potential opens voltage-gated calcium channels; calcium entry triggers vesicular acetylcholine release.
- Acetylcholine binds the two alpha subunits of the nicotinic receptor, a ligand-gated cation channel.
- End plate depolarisation reaches threshold and a muscle action potential propagates with calcium release from the sarcoplasmic reticulum.
- Acetylcholinesterase in the cleft terminates transmission; a large receptor safety margin exists.
- 2.
Contrast depolarising and non-depolarising block.
Show answer
- Depolarising: agonist holding the channel open; fasciculation then paralysis; no fade; no post-tetanic potentiation; anticholinesterase prolongs it.
- Non-depolarising: competitive antagonist; no fasciculation; fade and post-tetanic potentiation; reversible.
- Offset: plasma cholinesterase hydrolysis for suxamethonium; redistribution then organ clearance or Hofmann degradation for the others.
- Phase II block develops with prolonged exposure to a depolarising agent and behaves like a competitive block.
- 3.
Describe the pharmacology of suxamethonium.
Show answer
- Two linked acetylcholine molecules; agonist at the nicotinic receptor; hydrolysed by plasma cholinesterase.
- Fastest onset and shortest duration; independent of renal and hepatic clearance.
- Adverse: potassium release, myalgia, raised intragastric, intraocular and intracranial pressure, bradycardia, masseter spasm.
- Malignant hyperthermia trigger; prolonged in pseudocholinesterase deficiency.
- 4.
In which patients is suxamethonium dangerous and why?
Show answer
- Burns beyond about 24 hours until healed, denervation injuries after a few days, prolonged immobility and critical illness myopathy, chronic neuromuscular disease.
- Extrajunctional nicotinic receptor upregulation causes massive potassium release and risk of arrest.
- Also avoid in known hyperkalaemia, malignant hyperthermia susceptibility, and myotonic disorders.
- Alternative: a rapid-onset aminosteroid agent with reversal available.
- 5.
Compare atracurium with rocuronium.
Show answer
- Atracurium: benzylisoquinolinium, organ-independent elimination by Hofmann degradation and ester hydrolysis, useful in renal and hepatic failure; histamine release and the proconvulsant metabolite laudanosine.
- Rocuronium: aminosteroid, rapid onset, intermediate duration, hepatic and renal clearance so it accumulates in organ failure; little histamine release.
- Rocuronium can be reversed rapidly with sugammadex; atracurium cannot.
- Choice depends on onset needed, duration, organ function and haemodynamic tolerance.
- 6.
Which factors potentiate a non-depolarising block?
Show answer
- Hypothermia, acidosis, hypokalaemia, hypocalcaemia, hypermagnesaemia.
- Drugs: volatile anaesthetics, aminoglycosides, local anaesthetics, lithium.
- Disease: myasthenia gravis, Lambert-Eaton syndrome, severe hepatic and renal impairment.
- Resistance occurs with receptor upregulation and with chronic anticonvulsant therapy.
- 7.
How does neostigmine reverse a block, and what are its limitations?
Show answer
- Inhibits acetylcholinesterase, so acetylcholine accumulates and outcompetes the antagonist at the receptor.
- Ceiling effect: cannot reverse a deep block because acetylcholine accumulation is limited.
- Muscarinic effects require co-administration of an antimuscarinic: bradycardia, bronchospasm, salivation, gut activity.
- Will prolong a depolarising block, so the kind of block must be known.
- 8.
How does sugammadex work and when is it used?
Show answer
- Modified gamma-cyclodextrin that encapsulates aminosteroid molecules in plasma, forming an inactive complex.
- Creates a gradient drawing drug away from the junction, so even a deep block reverses within minutes.
- No muscarinic effects, so no antimuscarinic is needed; the complex is renally excreted.
- Effective only for aminosteroids; no effect on benzylisoquinoliniums or suxamethonium.
Practise this week
Week 13 in the other subjects
- Anatomy: Thoracic wall, pleura and lungs
- Pathology: Red cells, anaemia and haemostasis
- Physiology: Ventilation, dead space and V/Q matching
Not affiliated with the Australasian College for Emergency Medicine. Notes are a revision aid, not a substitute for the curriculum or for clinical guidelines.